Translate this page into:
Translational Biosensors for Biomarker Detection: From Analytical Innovation to Clinical Integration and Future Technology Development
* Corresponding author: Prof. Ali M. Yehia, Department of Chemistry, School of life and Medical Sciences, University of Hertfordshire Hosted by Global Academic Foundation, Egypt. ali.yehia@pharma.cu.edu.eg
-
Received: ,
Accepted: ,
How to cite this article: Mouhamed AA, Yehia AM. Translational Biosensors for Biomarker Detection: From Analytical Innovation to Clinical Integration and Future Technology Development. Sci Tech Nex. doi: 10.25259/STN_27_2025
Abstract
Objective
This review aims to describe the shift from traditional antioxidant supplements to modern, targeted therapies. It focuses on overcoming key problems like poor bioavailability and lack of specific cellular delivery that have limited older treatments.
Material and Methods
The analysis examines advanced delivery systems, including nanotechnology carriers such as liposomes and solid lipid nanoparticles. It also evaluates mitochondria-targeting agents like Mitoquinone and synthetic peptides, as well as enhanced formulations of plant-based compounds like curcumin and resveratrol.
Results
The findings show that nanotechnology carriers greatly improve the stability and absorption of antioxidants. Targeted agents successfully deliver antioxidants directly to mitochondria, the primary source of harmful molecules, showing benefits in heart, brain, and metabolic diseases. Advanced formulations of natural compounds make them more effective, often by boosting the body’s own defense systems.
Conclusion
The combination of nanotechnology, precise mitochondrial targeting, and enhanced natural compounds defines a new era of precision antioxidant medicine. Future success depends on confirming these benefits in human trials and designing personalized treatment strategies for complex age-related and chronic diseases.
Keywords
Artificial intelligence
Biomarkers
Biosensors
Nanomaterials
Translational challenges
1. INTRODUCTION
The field of modern medicine is undergoing a profound transformation, shifting from a reactive, symptom-based approach to a proactive, data-driven model. This evolution is fundamentally underpinned using biomarkers, which are defined as objectively measurable indicators of normal biological processes, pathogenic processes, or the body’s response to therapeutic interventions.[1]
These measurable entities span a diverse range, from molecular components such as DNA, RNA, proteins, and metabolites to physiological characteristics like blood pressure and imaging features.[1] Their clinical importance is multi-faceted, serving as essential tools for early disease detection, precise diagnosis, prognosis, and the monitoring of therapeutic efficacy.
The clinical utility of biomarkers is best understood through their application-based classification. This framework, formalized by initiatives such as the FDA-NIH Biomarker Working Group’s BEST (Biomarkers, Endpoints, and other Tools) Resource which provides a harmonized framework for defining and categorizing biomarkers according to their specific roles in research, diagnosis, and therapeutic monitoring. Such a structured approach facilitates the translation of biosensor-based biomarker discoveries into clinically meaningful tools.[1]
Biomarkers are classified based on their clinical utility into five main categories. Figure 1 illustrates the principal biomarker classes, spanning early detection through to treatment prediction. Diagnostic biomarkers are used to detect or confirm the presence of a disease or condition, such as cardiac troponin for myocardial infarction and prostate-specific antigen (PSA) for prostate cancer. Prognostic biomarkers help predict the likely outcome or course of a disease, independent of therapeutic intervention; examples include BRCA1/2 mutations for breast cancer and TP53 for estimating patient survival rates. Predictive biomarkers identify individuals who are likely to benefit from a specific therapeutic intervention, such as HER2 amplification in breast cancer and PD-L1 expression for predicting response to immunotherapy. Monitoring biomarkers are employed to assess the status of a disease or condition and to track the response to medical interventions, with HbA1c and blood glucose levels commonly used in diabetes management. Lastly, safety biomarkers are used to evaluate the adverse effects of therapeutic interventions or environmental exposures, exemplified by liver enzyme levels in cases of drug-induced toxicity.
- Biomarkers use range from detection to predicting treatment response.
This classification highlights a symbiotic relationship between the function of biomarkers and the technology used to measure them. For instance, diagnostic biomarkers necessitate a rapid, accurate, and specific detection method, perfectly aligning with the capabilities of point-of-care (POCT) biosensors.[2] Similarly, monitoring biomarkers, which require continuous data streams to track dynamic changes over time, are the ideal domain for wearable biosensing platforms. The need for sophisticated analysis of complex data to inform treatment decisions, as with predictive biomarkers, has propelled the integration of artificial intelligence (AI) into biosensor systems. This co-evolutionary relationship suggests that the future development of biosensor technology will be increasingly driven by the specific clinical application it is designed to serve, moving beyond generic analytical performance to highly tailored, purpose-built solutions. The rise of digital biomarkers—data derived from sensors and mobile technologies—is further reshaping this landscape, providing an unprecedented level of real-time, personalized health information.
The clinical utility of biomarkers is directly dependent on the ability to detect and quantify them with high sensitivity, specificity, and reliability.[3] Biosensors act as the crucial interface between a biological event and a quantifiable result, enabling this dynamic measurement.[1] A typical biosensor integrates a biological recognition element (e.g., an antibody, enzyme, or nucleic acid) with a physicochemical transducer, which converts the biological recognition event into a measurable signal, such as an electrical current, light emission, or a mass change.[1]
The intrinsic characteristics of biosensors, including their portability, rapid response, and cost-effectiveness, have made them indispensable tools for POCT. This represents a fundamental shift in healthcare delivery, decentralizing diagnostics from specialized laboratories and bringing them directly to the patient’s bedside, a physician’s office, or even into the home. By offering a continuous, dynamic snapshot of a patient’s physiological state, biosensors are pivotal to the realization of personalized medicine, where treatment strategies are tailored to an individual’s unique disease profile rather than a one-size-fits-all approach.[1] The continuous monitoring enabled by these devices facilitates more precise and patient-centric decision-making, such as informing prescription adjustments based on real-time data trends.
2. CORE PRINCIPLES OF BIOSENSING TECHNOLOGY
At its heart, a biosensor is an intricate analytical device built upon a common architectural framework. The successful translation of a biosensor from a laboratory concept to a clinical product hinges on the seamless integration and robust performance of each of its constituent parts.[4] A biosensor is typically composed of three fundamental components that work in concert to achieve its analytical purpose.[4] The first is biorecognition element, a biological or synthetic molecule designed to selectively bind to the target analyte. This element is the source of the sensor’s specificity, ensuring it identifies the target biomarker within a complex biological fluid. The second component is the transducer, a device that converts the physical or chemical change resulting from the binding event into a measurable signal, such as an electrical current, light emission, or mechanical force.[4] Finally, the signal processing unit interprets this transduced signal, filtering out noise and providing a quantitative or qualitative output that can be easily understood.[4] The overall performance of the biosensor, including its accuracy, precision, and reliability, is a direct function of the synergy between these three components.
2.1. A spectrum of biorecognition elements: The key to specificity
The choice of the biorecognition element is a critical design decision that defines a biosensor’s analytical performance and its suitability for clinical application. Traditionally, two types of biological molecules have dominated this role.[4]
Enzymes are widely used for their high specificity and catalytic activity. Glucose oxidase (GOx) is a quintessential example, employed in nearly all commercial glucose biosensors due to its remarkable ability to catalyze the oxidation of β-D-glucose.[5,6] This reaction produces gluconic acid and hydrogen peroxide (H2O2), and the detection of the latter serves as a proxy for glucose concentration. Beyond glucose, enzymatic biosensors have been used to detect lactate, cholesterol, and creatinine. Antibodies, the basis for immunosensors, are another cornerstone of biosensing due to their high binding affinity for specific antigens.[5] They are crucial for detecting biomarkers like cancer markers, proteins, and pathogens.
Despite their efficacy, biological receptors are not without their limitations. Enzymes can be susceptible to degradation, and the production of antibodies can suffer from batch-to-batch variability, posing significant hurdles for regulatory approval and manufacturing standardization.[5] These challenges have driven the search for more robust, next-generation alternatives.
Aptamers represent a promising group of bioreceptors that have gained considerable attention. These are small, single-stranded nucleic acid molecules (DNA or RNA) that can be selected to bind to specific targets with high affinity and selectivity.[7] Unlike antibodies, they are produced via chemical synthesis, which ensures consistent lot-to-lot quality and a reproducible target binding reaction. Their small size, typically 30 to 100 nucleotides, allows for efficient immobilization at high density on a sensor surface, simplifying miniaturization and automation. Furthermore, their superior stability and reusability, particularly for DNA aptamers, make them well-suited for long-term, continuous monitoring applications.[7]
Molecularly Imprinted Polymers (MIPs) are another revolutionary class of synthetic receptors. Often referred to as “synthetic antibodies” or “chemocavities,” MIPs are cross-linked polymers with specific binding sites created by synthesizing them in the presence of a target template molecule. This biomimetic design allows them to recognize and bind target molecules with high selectivity and chemical affinity. A key advantage of MIPs is their remarkable stability in challenging chemical environments and at high temperatures, with some surviving temperatures up to 300°C. This stands in stark contrast to natural proteins, which typically denature above 80°C. The use of aptamers and MIPs reflects a broader trend in the biosensing field: a deliberate pivot away from traditional biological receptors toward engineered, non-biological alternatives. This shift is not just about finding new ways to detect analytes; it is a strategic move to address the fundamental issues of reproducibility and long-term stability that have long hindered the clinical translation of biosensors. By engineering superior, more robust, and more manufacturable receptors, the field is laying the groundwork for a new generation of biosensors better suited for reliable, real-world application.
To further illustrate the advantages and limitations of various recognition elements, a comparative summary is presented in Table 1.
| Recognition element[8] | Stability | Reusability | Cost | Key advantages | Limitations |
|---|---|---|---|---|---|
| Enzymes | Moderate; sensitive to pH and temperature | Limited (usually single-use) | High | High catalytic activity and specificity | Denaturation and loss of activity over time |
| Antibodies | Moderate; sensitive to storage and temperature | Limited | High | High affinity and selectivity | Expensive production and short shelf life |
| Aptamers | High; stable over wide conditions | Good | Moderate | Chemically synthesized, easy regeneration | May show lower binding in complex matrices |
| MIPs | Very high; robust to temperature and solvents | Excellent | Low | Cost-effective, reusable, highly stable | Sometimes lower selectivity vs biological ligands |
MIPs: Molecular imprinted polymers
3. A COMPARATIVE ANALYSIS OF KEY BIOSENSOR PLATFORMS
The development of a biosensor platform involves making strategic trade-offs among analytical performance, portability, cost, and complexity. Each platform leverages different physical or chemical principles to achieve its goals, making some better suited for specific applications than others [Table 2]. A comparative overview of the most prominent platforms reveals their unique strengths and limitations.
| Platform | Key principles | Advantages | Limitations | Primary applications[5] |
|---|---|---|---|---|
| Electrochemical | Measures electrical changes (current, potential, impedance) from a biochemical reaction. | High sensitivity, portability, cost-effective, easily miniaturized. | Prone to interference in complex biological matrices. | Glucose monitoring, lactate detection, cancer biomarker assays. |
| Optical | Measures changes in light properties (e.g., fluorescence, absorbance, refractive index). | Ultra-low detection limits, high sensitivity, often label-free detection. | Requires sophisticated instrumentation, more complex to miniaturize. | DNA sequencing, protein detection, drug discovery. |
| Paper-based | Relies on capillary action for passive fluid transport on a porous substrate. | Affordability, disposability, portability, low power consumption. | May lack long-term stability; limited long-term reproducibility. | POCT in resource-limited settings, infectious disease detection, metabolic monitoring. |
| Wearable | Continuous, non-invasive monitoring of physiological and biochemical signals. | Real-time data streams, personalized health insights, proactive healthcare. | Biofouling, data integration challenges, stability of biorecognition elements. | Diabetes management, cardiovascular disease monitoring, general wellness tracking. |
POCT : Point-of-care technology
3.1. Electrochemical biosensors
Electrochemical biosensors stand out for their robust performance, portability, and cost-effectiveness.[1,9] They operate by converting a biochemical event into a measurable electrical signal, such as a change in electric current (amperometry), potential (potentiometry), or conductance (conductometry).[5] This technology is the cornerstone of many commercial diagnostic devices, with continuous glucose monitors (CGMs) representing a prime example.[1] The principles of electrochemical biosensing have been successfully applied to detect a wide array of biomarkers, including glucose, lactate, cholesterol, urea, and creatinine, all of which are vital indicators of metabolic and renal function. Their ability to detect trace levels of analytes in biofluids such as blood, urine, or saliva has also made them a favored choice for early cancer biomarker detection.
3.2. Optical biosensors
Optical biosensors utilize light-based techniques to detect and quantify a plethora of substances. They function by measuring changes in optical properties, such as absorbance, fluorescence, or surface plasmon resonance (SPR), that occur when an analyte binds to a biorecognition element.[5] The key strengths of optical biosensors are their exceptional sensitivity, which allows for ultra-low detection limits, and the ability to perform label-free detection, which simplifies the assay procedure and reduces the risk of interference. Specific examples include fluorescence-based biosensors, which offer high specificity and are used in DNA sequencing and protein detection, and Surface Plasmon Resonance (SPR) biosensors, which are highly sensitive and widely used in drug discovery and environmental monitoring.[10]
3.3. Paper-based biosensors
Paper-based biosensors, or paper-based analytical devices (PADs), represent a transformative technology for democratizing diagnostics.[11] They capitalize on the inherent properties of paper, such as its porosity, flexibility, and capillary action, to create affordable, portable, and user-friendly devices. These devices can transport fluid without external pumps or power sources, making them ideal for point-of-care (POC) applications, especially in resource-limited settings where traditional laboratory equipment is inaccessible.[11] This design and material choice directly address the cost and infrastructure barriers to healthcare in developing nations and rural areas. Simple and scalable fabrication methods like wax printing, screen printing, and even pen-on-paper techniques make them highly cost-effective for mass production. The strategic design choices behind paper-based sensors—their reliance on passive fluid transport and minimal electronic components—have profound implications for global health equity. By providing an accessible and affordable platform for diagnostics, they facilitate timely disease detection and public health surveillance in areas where it was previously impossible.
3.4. Wearable biosensors
Wearable biosensors are a class of non-invasive devices integrated into smartwatches, adhesive patches, or smart fabrics that provide continuous, real-time monitoring of physiological and biochemical parameters.[12] These devices have fundamentally altered chronic disease management, particularly for conditions like diabetes and cardiovascular diseases.[13] By providing a continuous data stream of biomarkers such as glucose levels, heart rate, and blood oxygen saturation, they move healthcare from a reactive, episodic model to a proactive, continuous one. The ability to track biomarkers in alternative biofluids like sweat, saliva, and tears is also being explored, offering the potential for continuous monitoring without invasive finger-prick tests.[1] The continuous data generated by wearable biosensors enables clinicians to make more personalized and precise decisions regarding medication and treatment.
4. NAVIGATING THE TRANSLATIONAL CHALLENGES
Despite the remarkable progress in biosensing research, a significant gap persists between laboratory innovation and real-world clinical application. This translational hurdle is primarily driven by persistent analytical and practical challenges that compromise a biosensor’s reliability and long-term performance.
4.1. The critical challenge of analytical performance
For a biosensor to be clinically useful, it must satisfy a set of stringent analytical criteria. The most critical of these are specificity, accuracy, and precision. Specificity ensures that the sensor selectively identifies the target biomarker without interference from other compounds in the sample.[1] Accuracy reflects the closeness of a measured value to the true concentration of the biomarker, while precision relates to the reproducibility of measurements. These figures of merit are often compromised in real-world settings by issues such as matrix effects, signal drift, and biofouling. Mitigation of these challenges are summarized in [Table 2].
4.2. The problem of matrix effects
The matrix effect is a phenomenon where components of a complex biological sample, such as salts, lipids, or other proteins, either suppress or enhance the sensor’s signal, leading to an inaccurate measurement of the target analyte.[14] This issue is particularly pronounced in complex biofluids like blood and sweat. A range of strategies has been developed to mitigate this problem. One fundamental approach is sample purification using methods like solid-phase extraction (SPE) or liquid-liquid extraction (LLE) to remove interfering components before analysis. Alternatively, matrix minimization through sample dilution can be effective if the biosensor has sufficient sensitivity to spare. For more sophisticated platforms, advanced engineering solutions are required. The presence of other compounds can affect fundamental sensor properties, as demonstrated by the impact of varying electrolyte matrices on the Fermi level of graphene-based FET biosensors. To address this, a multichannel chip design has been developed that allows for in-situ calibration using a negative control, providing a real-time method to regulate the matrix effect and statistically validate results. This demonstrates that overcoming the matrix effect often requires not just a chemical purification step but an integrated, multi-channel engineering solution to ensure accuracy in complex, real-world samples (Table 3).
| Challenge | Description of the problem | Examples of proposed solutions[17] |
|---|---|---|
| Matrix effects | Signal suppression or enhancement caused by interfering components in complex biological samples. | Sample purification (SPE, LLE), sample dilution, multichannel biosensor design with in-situ calibration. |
| Signal drift | A gradual, spurious change in the sensor’s baseline signal over time, often due to molecular reorganization. | Incorporating a “conditioning step” prior to use, designing new biosensor materials (e.g., polymer linkers) with inherent stability. |
| Biofouling | Non-specific adsorption of proteins and other biomolecules, which masks the sensor surface. | Passive: Use of hydrophilic/superhydrophobic surfaces, zwitterionic polymers, drug-eluting materials. Active: Stimuli-responsive materials (temperature/pH), acoustic waves, magnetic actuators. |
SPE: Solid-phase extraction; LLE: Liquid-liquid extraction
4.3. Ensuring long-term stability and reliability
A biosensor’s long-term utility, especially for chronic monitoring, is contingent on its stability and reliability over time. Two major issues that compromise this are signal drift and biofouling. Signal drift is a gradual change in the sensor’s baseline signal that can be mistakenly attributed to an analyte binding event.[15] This is often caused by the reorganization of surface molecules on the transducer, such as the self-assembled monolayers (SAMs) on a gold electrode. The use of a “conditioning step” to stabilize the baseline has been a partial solution, but its variable duration has limited its use in rapid POCT devices. An advanced approach involves developing new, more stable materials, such as polymer-based surface linkers, that inherently exhibit negligible drift.
Biofouling is the non-specific adsorption of proteins, cells, or other biomolecules onto the sensor surface, which physically masks the biorecognition element and degrades the signal. To combat this, a variety of anti-biofouling strategies have been developed, divided into two categories: passive and active.[16] Passive strategies involve modifying the sensor surface with materials that are thermodynamically unfavorable for fouling, such as hydrophilic or superhydrophobic surfaces, or using drug-eluting coatings that release anti-inflammatory agents to suppress the host’s immune response.[16] Active strategies involve the physical removal of adhered fouling elements. This can be accomplished using stimuli-responsive materials (e.g., poly(N-isopropylacrylamide), or PNIPAAm), which can swell and deswell in response to changes in temperature, or by applying acoustic waves to selectively remove non-specific proteins.[16] The persistence of signal drift and biofouling highlights that the most significant translational challenges for biosensors are not just about initial analytical performance but about maintaining that performance in a dynamic, unpredictable biological environment. Solutions must therefore be multidisciplinary, bridging the gap between material science, surface chemistry, and electronic engineering to create devices that are inherently robust and reliable for long-term use.
5. NANOTECHNOLOGY FOR ENHANCED PERFORMANCE
Nanomaterials have emerged as a central pillar of modern biosensor design, providing unique properties that can dramatically enhance sensitivity, specificity, and portability.[3] [Table 4] represents the function and the mechanism advanced nanomaterials applied in biosensors like gold nanoparticles (GNPs), carbon nanotube (CNTs) and quantum dots (QDs).
| Nanomaterial | Function in biosensing | Mechanism | Applications |
|---|---|---|---|
| Gold nanoparticles (GNPs) | Signal amplification; active plasmonic material for optical sensing. | Enhance signal amplification efficiency by up to 50% in electrochemical sensors; provide a colorimetric signal in optical assays. | Tumor marker detection, colorimetric assays for E. coli.[18,19] |
| Carbon nanotubes (CNTs) | Transducer; increase surface area and conductivity. | Exhibit a massive increase in conductivity and improved electron transfer. CNT-based FETs enable ultra-sensitive, low-noise detection. | Cancer biomarker detection, rapid diagnosis of infectious diseases (e.g., COVID-19).[18] |
| Quantum dots (QDs) | Fluorescent label; signal transduction. | Superior fluorescent properties (high photostability, broad excitation, narrow emission) enable ultra-low detection limits in the picomolar to attomolar range. | DNA sequencing, protein detection, ultra-sensitive diagnostics.[20] |
Gold Nanoparticles (GNPs) are highly versatile, serving as both signal amplifiers in electrochemical sensors and as active plasmonic materials in optical detection.[20] Their use can boost signal amplification efficiency by up to 50% in electrochemical devices. Furthermore, their unique optical properties allow for colorimetric bioassays where the presence of an analyte causes a visible color change, making them detectable by simple devices like smartphones.[18,21]
Carbon Nanotubes (CNTs) are prized for their high electrical conductivity and surface-to-volume ratio. As transducers, they can significantly increase electron transfer, leading to enhance sensitivity. The use of CNT-based field-effect transistor (FET) biosensors has enabled the ultra-sensitive and rapid diagnosis of infectious diseases like COVID-19, showcasing their potential for fast and robust detection.[18]
Quantum Dots (QDs) are semiconductor nanocrystals with exceptional fluorescent properties, including superior photostability and a broad excitation spectrum with a narrow, adjustable emission.[20] When integrated into biosensors, they enable detection at extremely low concentrations, from the picomolar to attomolar range. A key challenge with QDs is the toxicity of heavy metals in their composition, which has led to a push for the development of safer, carbon-based QDs.[22]
6. NEXT-GENERATION ADVANCEMENTS AND FUTURE DIRECTIONS
The next phase of biosensor development is moving beyond incremental improvements and toward fundamental, platform-level innovations. These advancements are driven by the integration of cutting-edge technologies that are poised to transform the capabilities and applications of biosensors.
6.1. The synergy of AI and data analytics
The role of artificial intelligence (AI) and machine learning (ML) in biosensor systems is moving beyond mere data processing to become a core, integral component of the diagnostic workflow.[23] The data generated by biosensors is often complex, voluminous, and subject to noise, necessitating advanced analytical techniques to extract meaningful insights. AI algorithms can interpret these complex data streams to generalize patterns, identify anomalies, and determine health outcomes with a high degree of accuracy and speed.[23]
AI-powered biosensors have demonstrated a transformative impact on diagnostic performance. For instance, a recent study showed that using convolutional neural networks (CNNs) to analyze electrochemical biosensor signals improved cancer biomarker detection accuracy by over 900% compared to conventional approaches. In diabetes management, Long Short-Term Memory (LSTM) networks were able to predict variations in glucose levels with a mean absolute error (MAE) 32% lower than traditional linear regression models. AI also enables predictive modelling based on historical biosensor data, allowing for the forecasting of health events and the automation of alerts. This capability is critical in clinical settings where timely and accurate diagnosis is paramount. By integrating AI, biosensors can deliver personalized health insights without requiring expert interpretation, making them more accessible for remote and decentralized diagnostics.[24]
6.2. Integration with digital health ecosystems
The ultimate utility of next-generation biosensors lies in their seamless integration with digital health ecosystems. The convergence of biosensors with the Internet of Things (IoT), mobile health (mHealth) applications, and cloud computing enables continuous, real-time monitoring and data transmission to healthcare providers.[25] This integrated approach facilitates remote patient monitoring and shifts the focus of healthcare from reactive treatment to proactive and preventative care.[26] For example, wearable biosensors can transmit heart rate and glucose data to a physician’s dashboard, allowing for smarter medication choices based on detailed, continuous data trends.
The move toward an integrated platform for health monitoring fundamentally redefines the biosensor itself. The device is no longer just a standalone tool for a single measurement; it is a data acquisition point for a broader system that includes AI for interpretation and a digital platform for data management and clinical action. The true value of a modern biosensor system comes from the data it collects, the intelligence it generates, and its integration with a secure ecosystem that can act on that intelligence. This shift, however, introduces new challenges, including the need for universal technological standardization and the critical issue of ensuring the security and privacy of sensitive patient data.
6.3. Emerging clinical applications
As biosensor technology matures, its applications are becoming increasingly specific and targeted. The field is moving from proof-of-concept demonstrations to the development of highly specialized diagnostic panels for complex diseases. For example, biosensors are being developed for advanced cancer diagnostics, not only for early detection but also for analyzing cancer-associated microRNA.[5] In the context of acute conditions, innovative biosensors have been designed for the detection of a panel of stroke biomarkers, including N-terminal pro B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), and cardiac troponins. The ability to simultaneously detect multiple biomarkers with high sensitivity in complex biological samples is crucial for providing timely diagnostic and prognostic information to facilitate life-saving interventions.
Therapeutic Drug Monitoring (TDM), offering a flexible and precise method for real-time monitoring of drug levels and physiological responses. This capability is a significant improvement over traditional, often expensive, laboratory methods like HPLC and immunoassays, which cannot provide continuous, real-time feedback.
7. CONCLUSION
From Laboratory to Lifesaving Application The evolution of biosensors for biomarker detection is a testament to the power of interdisciplinary innovation. The field has moved from simple, single-analyte laboratory prototypes to complex, integrated systems that are poised to revolutionize clinical diagnostics and personalized medicine. The journey has been marked by a fundamental transition from centralized, episodic testing to decentralized, continuous monitoring. This shift has been driven by key advancements, including the adoption of more stable, reproducible synthetic bioreceptors like aptamers and molecularly imprinted polymers; the pervasive use of nanomaterials to enhance analytical performance; and the transformative integration of AI to interpret complex data and provide predictive insights.
Despite these breakthroughs, the successful clinical translation of biosensors hinges on a concerted effort to overcome remaining challenges, particularly those related to analytical performance in real-world environments. Addressing issues such as matrix effects, signal drift, and biofouling requires a deep understanding of the molecular and material science at the sensor-sample interface. The future of biosensing lies not in creating a singular “super sensor” but in developing a robust and secure platform where the physical device is just one component of a broader digital health ecosystem. By creating systems that can acquire, interpret, and transmit actionable bio-intelligence in real-time, biosensors can empower both clinicians and patients, enabling a more proactive, personalized, and equitable approach to healthcare worldwide.
8. TECHNOLOGY DEVELOPMENT PERSPECTIVE OF BIOSENSORS
The technological implications of this work lie in positioning biosensors as pivotal tools that bridge molecular discovery with real-time clinical application. Integrating nanomaterials, synthetic biorecognition systems such as aptamers and molecularly imprinted polymers, and AI-driven analytics has transformed biosensors from simple detectors into intelligent diagnostic platforms. These advances enable rapid, decentralized, and personalized monitoring, supporting the shift toward preventive and precision healthcare. Their incorporation into wearable and mobile systems further allows continuous and automated data acquisition and transmission, strengthening the link between patient-generated data and clinical decision-making. However, several technological gaps still hinder full clinical translation. Issues such as matrix effects, signal drift, and biofouling continue to compromise measurement stability and reproducibility. A lack of standardized fabrication and data integration protocols limits regulatory approval and large-scale deployment. Furthermore, continuous biosensing raises challenges in cybersecurity and data management, necessitating robust frameworks for interoperability, reliability, and patient privacy. Future development should focus on integrating biosensors within intelligent digital health ecosystems rather than as stand-alone devices. Innovations in self-calibrating and anti-fouling materials, multi-analyte sensing, and AI-based signal correction will enhance long-term stability and accuracy. Coupling biosensors with Internet of Things (IoT) architectures and cloud-based analytics will allow proactive disease prediction and real-time therapeutic feedback. The interdisciplinary relevance of this technology spans analytical chemistry, materials science, biomedical engineering, and data science, with potential applications in pharmaceuticals, environmental monitoring, and food safety. By converging these fields, biosensors represent a cornerstone technology linking fundamental science with translational impact, embodying the mission of Science and Technology Nexus to merge analytical innovation with tangible clinical and societal benefit.
Ethical approval
Institutional Review Board approval is not required.
Declaration of patient consent
Patient’s consent not required as there are no patients in this study.
Financial support and sponsorship
Nil
Conflicts of interest
Dr. Ali Yehia is on the Editorial Board of the Journal.
Use of artificial intelligence (AI)-assisted technology for manuscript preparation
The authors confirm that they have used artificial intelligence (AI)-assisted technology for assisting in the writing and editing of the introduction part in the manuscript.
References
- Chapter Response Biomarker. 2021;32:480-8.
- Analytical Chemistry. 2012;84:487-15.
- Experimental Biology and Medicine (Maywood, N.J.). 2018;243:213-21.
- In Essays In Biochemistry. 2016;60:1-8.
- Molecules. 2022;27:7327.
- Talanta Open. 2025;12:100519.
- Sensors. 2008;8:4296-307.
- Springer International Publishing; 2025. p. :33-74.
- Sensing and Bio-Sensing Research. 2025;50:100881.
- Photonics Research. 2025;13:698-708.
- Engineering Proceedings. 2025;106:8.
- Sensors and Actuators A: Physical. ;376:115617.
- Biosensors. 2024;14:560. Multidisciplinary Digital Publishing Institute (MDPI)
- In Materials. 2024;17:312. 2. Multidisciplinary Digital Publishing Institute (MDPI)
- ACS Sensors. 2021;6:3340-47.
- Microchimica Acta. 2024;191:138.
- Micromachines. 2018;9:564.
- Nanoscale Advances. 2022;5:992-1010.
- Precious Metals for Biomedical Applications. 2014;77:163-76.
- Biosensors and Bioelectronics: X. 2023;14:1000375.
- RSC Advances. 2023;13:23138-146.
- IECB 2025. 2025;106:1-10.
- International Journal of Scientific Development and Research. 2023;8:388.
- The Role of Artificial Intelligence in Advancing Biosensor Technology: Past, Present, and Future Perspectives. Advanced Materials 2025:2504796.
- [Google Scholar]
- Frontiers Media SA. 2023;11
- Wearable sensors: modalities, challenges, and prospects. Lab on a Chip. 2018;18:217-248.
- [Google Scholar]